Valneva SE
| Company type | Societas Europaea |
|---|---|
| Euronext Paris: VLA
CAC Mid 60 | |
| ISIN | FR0004056851 |
| Industry | Biotechnology |
| Predecessor | Merger of Intercell and Vivalis SA |
| Founded | 2013 |
| Headquarters | , |
Key people | Thomas Lingelbach (CEO), Anne-Marie Graffin (Chairwoman of the Board of Directors) |
| Products | Development of vaccines |
| Website | www |
Valneva SE is a specialty vaccine company registered in Saint-Herblain, France, developing, producing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States.